SC 13G/A | 2018-02-14 | Flynn James E | Aclaris Therapeutics, Inc. | 2,233,416 | 7.2% | EDGAR |
SC 13G/A | 2018-02-13 | FMR LLC | Aclaris Therapeutics, Inc. | 2,673,260 | 8.7% | EDGAR |
SC 13G/A | 2018-02-05 | FRANKLIN RESOURCES INC | Aclaris Therapeutics, Inc. | 2,596,814 | 8.4% | EDGAR |
SC 13G | 2018-02-01 | BlackRock Inc. | Aclaris Therapeutics, Inc. | 2,195,028 | 7.1% | EDGAR |
SC 13D/A | 2017-11-16 | VIVO VENTURES VII, LLC | Aclaris Therapeutics, Inc. | 1,700,298 | 5.5% | EDGAR |
SC 13D/A | 2017-10-20 | VIVO VENTURES VII, LLC | Aclaris Therapeutics, Inc. | 2,401,398 | 8.0% | EDGAR |
SC 13G | 2017-10-10 | Flynn James E | Aclaris Therapeutics, Inc. | 1,769,377 | 5.9% | EDGAR |
SC 13G/A | 2017-08-15 | FMR LLC | Aclaris Therapeutics, Inc. | 3,114,457 | 10.4% | EDGAR |
SC 13D/A | 2017-08-14 | VIVO VENTURES VII, LLC | Aclaris Therapeutics, Inc. | 2,858,569 | 9.5% | EDGAR |
SC 13D/A | 2017-03-03 | VIVO VENTURES VII, LLC | Aclaris Therapeutics, Inc. | 2,858,569 | 13.3% | EDGAR |
SC 13G/A | 2017-02-14 | FMR LLC | Aclaris Therapeutics, Inc. | 1,627,229 | 6.4% | EDGAR |
SC 13G/A | 2017-02-14 | RA CAPITAL MANAGEMENT, LLC | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2017-02-14 | PERCEPTIVE ADVISORS LLC | Aclaris Therapeutics, Inc. | 1,260,847 | 5.9% | EDGAR |
SC 13G/A | 2017-02-08 | FRANKLIN RESOURCES INC | Aclaris Therapeutics, Inc. | 1,527,549 | 5.9% | EDGAR |
SC 13D/A | 2017-01-18 | Sofinnova Venture Partners VIII, L.P. | Aclaris Therapeutics, Inc. | 1,539,480 | 5.9% | EDGAR |
SC 13G/A | 2016-12-21 | FMR LLC | Aclaris Therapeutics, Inc. | 1,931,727 | 7.6% | EDGAR |
SC 13D/A | 2016-11-21 | VIVO VENTURES VII, LLC | Aclaris Therapeutics, Inc. | 3,283,569 | 15.3% | EDGAR |
SC 13G/A | 2016-10-06 | RA CAPITAL MANAGEMENT, LLC | Aclaris Therapeutics, Inc. | 1,530,020 | 7.1% | EDGAR |
SC 13G/A | 2016-04-21 | FMR LLC | Aclaris Therapeutics, Inc. | 2,789,898 | 13.8% | EDGAR |
SC 13G/A | 2016-02-16 | RA CAPITAL MANAGEMENT, LLC | Aclaris Therapeutics, Inc. | 2,564,553 | 12.7% | EDGAR |